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Abstract
Background: The a7 nicotinic acetylcholine receptors (nAChRs) play an important role in the pathophysiology of
neuropsychiatric diseases such as schizophrenia and Alzheimer’s disease. The goal of this study was to evaluate the two
carbon-11-labeled a7 nAChR agonists [
11C]A-582941 and [
11C]A-844606 for their potential as novel positron emission
tomography (PET) tracers.
Methodology/Principal Findings: The two tracers were synthesized by methylation of the corresponding desmethyl
precursors using [
11C]methyl triflate. Effects of receptor blockade in mice were determined by coinjection of either tracer
along with a carrier or an excess amount of a selective a7 nAChR agonist (SSR180711). Metabolic stability was investigated
using radio-HPLC. Dynamic PET scans were performed in conscious monkeys with/without SSR180711-treatment. [
11C]A-
582941 and [
11C]A-844606 showed high uptake in the mouse brain. Most radioactive compounds in the brain were detected
as an unchanged form. However, regional selectivity and selective receptor blockade were not clearly observed for either
compound in the mouse brain. On the other hand, the total distribution volume of [
11C]A-582941 and [
11C]A-844606 was
high in the hippocampus and thalamus but low in the cerebellum in the conscious monkey brain, and reduced by
pretreatment with SSR180711.
Conclusions/Significance: A nonhuman primate study suggests that [
11C]A-582941 and [
11C]A-844606 would be potential
PET ligands for imaging a7 nAChRs in the human brain.
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Introduction
The nicotinic acetylcholine receptors (nAChRs) are ligand-
gated ion channels that are distributed throughout the human
central nervous system (CNS) and that each consist of five subunits
(a combination of a and b subunits). At present, nine a (a2–a10)
and three b (b2–b4) subunits have been identified in humans [1].
Among the several nAChRs subtypes in the CNS, the homomeric
a7 and heteromeric a4b2 subtypes are predominant in the brain
[2]. These subtypes are best characterized in terms of their ligand
selectivity, since they can be studied by means of binding
techniques: [
3H]cytisine or [
3H]nicotine can label a4b2 nAChRs,
and [
125I]a-bungarotoxin or [
3H]methyllycaconitine ([
3H]MLA) is
used to label a7 nAChRs [3]. In the mouse brain, high
concentrations of a7 nAChRs are found in the pons, hippocampus
and colliculi [4]. In the rat brain, high densities of a7 nAChRs are
found in the hippocampus, hypothalamus, and cortical areas,
whereas they are expressed to lesser degrees in the striatum and
cerebellum [5]. Although the distribution of a7 nAChRs in
primates is still not completely known, the available data suggest
that it does not differ greatly, overall, from that in rodents. The a7
nAChRs are most dense in the thalamic nuclei and moderately
dense in the hippocampus, prefrontal cortex, caudate, putamen,
and substantia nigra in the monkey brain [6].
Several lines of evidence suggest that a7 nAChRs play a role in
the pathophysiology of neuropsychiatric diseases such as schizo-
phrenia, Alzheimer’s disease, anxiety, depression, and drug
addiction, and that a7 nAChRs are the attractive therapeutic
targets for these diseases [2,7–15]. Studies using postmortem
human brain samples have demonstrated alterations in the levels
of a7 nAChRs in the brains of patients with schizophrenia [16,17]
and Alzheimer’s disease [18–20]. It is thus of great interest to
examine whether a7 nAChRs are altered in the living brain of
patients with neuropsychiatric diseases such as schizophrenia and
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occupancy of potential therapeutic a7 nAChR drugs in the intact
human brain. Therefore, several researchers have made an effort
to develop radioligands that can be used to selectively and
quantitatively examine the distribution of a7 nAChRs in the
human brain with positron emission tomography (PET) and single
photon emission computed tomography (SPECT). However, the
development of such radioligands has been challenging due to a
lack of lead structures with high affinity and with functional groups
that can be labeled with PET and SPECT radioisotopes.
Recently, our group developed the 1,4-diazabicyclo-[3.2.2]non-
ane analog 4-[
11C]methylphenyl 2,5-diazabicyclo[3.2.2]noane-2-
carbocylate ([
11C]CHIBA-1001) and confirmed its selective uptake
in the conscious monkey brain by PET [21]. Until now,
[
11C]CHIBA-1001 has been the only PET ligand available for
clinical trials employing a7 nAChR imaging in the human brain
[22]. While [
11C]CHIBA-1001 demonstrates some a7 nAChR-
selective properties, we considered that it would be beneficial to
identify another lead structure, and began a search for a more
suitable PET radioligand for imaging a7 nAChRs in the human
brain. Recently, a new series of octahydropyrrolo[3,4-c]pyrrole
derivatives were described by Abbott Laboratories as ligands for
the nAChRs [23,24]. We chose two octahydropyrrolo[3,4-
c]pyrrole derivatives as selective a7 nAChRs agonists for labeling
with carbon-11, 2-methyl-5-[6-phenylpyridazine-3-yl]octahydro-
pyrrolo[3,4-c]pyrrole (A-582941) and 2-(5-methyl-hexahydro-pyr-
rolo[3,4-c]pyrrol-2-yl)-xanthene-9-one (A-844606), since these
compounds were previously reported to be potent and selective
a7 nAChR agonists. A-582941 displaced specific binding of the a7
nAChR radioligand [
3H]A-585539 to membranes of the rat brain
and human frontal cortex with Ki values of 10.8 and 17 nM,
respectively [25,26]. In contrast, A-582941 was found to have
much lower affinity for heteromeric a4b2 subtypes, as measured
using [
3H]cytisine binding to rat brain membranes
(Ki.100,000 nM) [26]. Also, A-582941 (10 mM) did not show
significant displacement of binding of .75 binding sites, with the
single exception being 5-HT3 receptors, in which it displaced
[
3H]-BRL 43694 (Granisetron) binding (.85% at 10 mM). The Ki
value of A-582941 for 5-HT3 receptors was 154 nM, which was
,15-fold higher than that for a7 nAChRs. A-844606 displaced
[
3H]MLA binding to the rat brain membrane with an IC50 value
of 11 nM [27]. In contrast, A-844606 exhibited negligible
displacement of [
3H]cytisine binding to a4b2 nAChRs
(IC50.30,000 nM) [27].
The goal of this study was to radiolabel the two potent and
selective a7 nAChR agonists A-582941 and A-844606 with the
positron emitter carbon-11, and to evaluate their potential for the
in vivo imaging of a7 nAChRs in the human brain.
Results
Radiosynthesis
Radiosynthesis of [
11C]A-582941 and [
11C]A-844606 by N-
[
11C]-methylation of the desmethyl precursor was carried out
under various concentrations of NaOH as a base (Figure 1). The
use of [
11C]methyl triflate in acetone with two equimolar amounts
of NaOH led to a sufficient radiochemical yield of each
compound. The radiochemical yields using [
11C]methyl triflate
under these conditions for [
11C]A-582941 and [
11C]A-844606
were 16.8611.98% (n=8) and 40.0616.8% (n=7), respectively.
Large excess or equimolar amounts of NaOH as a base led to a
slight decrease of the radiochemical yields of [
11C]A-582941
(10.3% for equimolar; 13.2% for 10 equimolar). The total
preparation time for each tracer, including purification and
formulation, was approximately 30 min from the end of
irradiation. The radiochemical purities of each tracer were over
97%, and the specific activities at 30 min after the end of
irradiation were in the range of 15–108 GBq/mmol for each
radiotracer. The absence of any residual traces of the starting
materials was verified by high performance liquid chromatography
(HPLC) analysis.
Tissue Distribution Study
The results of the tissue distribution studies of the two
radiotracers in mice are summarized in Tables 1 and 2. The
highest initial uptake (percentage of injected doses per gram of
tissue: %ID/g) of [
11C]A-582941 was found in the lungs followed
by the kidneys, pancreas, heart, liver, small intestines, spleen, brain
and muscle (Table 1). The radioactivity level of [
11C]A-582941
was low in the blood. The level of radioactivity in the brain
increased for the first 5 min and then gradually decreased. The
highest initial uptake (%ID/g) of [
11C]A-844606 was found in the
lungs followed by the kidneys, heart, brain, pancreas, small
intestines, muscle, liver and spleen (Table 2). The radioactivity
levels of [
11C]A-844606 were low in the blood. The level of
radioactivity in the brain increased gradually, peaked at 30 min,
and then decreased.
To detect the specific binding for a7 nAChRs, a blocking
experiment was carried out using the selective a7 nAChR agonists
(SSR180711, unlabeled A-582941 or A-844606), and the selective
a4b2 nAChR agonist A-85380 (Tables 3, 4, 5, and 6). In vehicle-
treated mice, the hippocampal (a7 rich) uptake of [
11C]A-582941
was not significantly higher than the cerebellar (a7 poor) uptake at
15 min after injection. In contrast, the hippocampal uptake of
[
11C]A-844606 in vehicle-treated mice was slightly higher than the
cerebellar uptake at 30 min after injection, although the difference
was not statistically significant. None of the three compounds
(SSR180711, A-85380 or A-844606) decreased the uptake of
[
11C]A-582941 in brain tissues, with the exception of SSR180711
in the medulla oblongata (Table 3). Carrier-loading decreased the
uptake of [
11C]A-582941 in the medulla oblongata and midbrain
(Table 4). In the case of [
11C]A-844606, co-injection of the three
compounds (SSR180711, A-85380 and A-582941) did not
decrease the uptake of [
11C]A-844606 in brain tissues (Table 5).
In contrast, carrier-loading decreased the uptake of [
11C]A-
844606 in all the regions of the brain tissues (Table 6).
Metabolite Analysis
By deproteinization, most of the radioactivity of the plasma and
brain tissues was recovered in the soluble fraction in the metabolite
analysis of [
11C]A-582941 (.95%) and [
11C]A-844606 (.85%).
HPLC analysis of the plasma showed two major labeled
metabolites in addition to [
11C]A-582941 (retention time=6.4 -
min). The retention times of the two major metabolites were 2.4
and 4.3 min. In contrast, these metabolites were present at only
negligible levels in the brain. At 15 min after injection of [
11C]A-
582941, the percentages of the unchanged form in the brain and
plasma were 95.461.9% and 40.567.1% (n=3), respectively, and
the corresponding figures were 97.460.8 and 26.866.6% (n=3)at
30 min after injection. Similarly, in the case of [
11C]A-844606,
two major labeled metabolites were found in the plasma (retention
times=2.0 and 4.0 min) in addition to [
11C]A-844606 (retention
time=8.8 min). Again, these metabolites were present at only
negligible levels in the brain. The percentages of the unchanged
form in the brain and plasma were 95.961.8% and 39.663.4%
(n=3), respectively, at 15 min, and 94.9% (n=2) and 28.965.1%
(n=3), respectively, at 30 min.
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Figure 2 shows the static and corresponding parametric total
distribution volume (VT) images of [
11C]A-582941 in the brain of a
conscious monkey at baseline and under SSR180711-blocking
conditions. Blocking effects by pretreatment with SSR180711 are
seen in both images. Figure 3 shows their time-activity curves
(TACs) in the four brain regions. In the baseline scan (n=4),
radioactivity in the four brain regions (the thalamus, frontal cortex,
hippocampus, and cerebellum) peaked at 10 min. The highest
accumulation of radioactivity was found in the thalamus, but the
regional differences were small. Under the SSR180711-blocking
condition, the radioactivity level peaked slightly earlier and
decreased slightly more quickly.
The total and metabolite-corrected plasma radioactivity
levels decreased rapidly (data not shown). Thin-layer chroma-
tography (TLC) analysis revealed that the percentages of the
unchanged form of [
11C]A-582941 decreased rapidly at baseline
(n=4): 93.362.7%, 91.661.9%, 89.961.2%, 81.662.8%,
71.664.1%, 42.867.8%, 34.067.4%, 26.965.3%, 23.063.4%,
and 19.262.6%; and under the SSR180711-blocking condition
(n=1): 93.2%, 93.9%, 93.0%, 74.2%, 56.7%, 28.3%, 23.2%,
20.4%, 22.2%, and 15.9% at 0.3, 0.7, 1.1, 6.0, 10, 30, 45, 60,
75, and 90 min, respectively.
In Logan graphical analysis, the rank order of VT values
(mean 6 SD; range) was the thalamus (30.464.1; 24.6–34.0). frontal
cortex (29.264.7; 23.2–34.5). hippocampus (28.063.8; 22.8–31.6).
cerebellum (23.063.4; 18.0–25.4). Pretreatment with SSR180711
significantly decreased VT (,30%) (Table 7).
Figures 4 and 5 show the static and VT images of [
11C]A-
844606, and their TACs, respectively, in a monkey brain in
baseline and SSR180711-blocking conditions. The blocking effect
by pretreatment with SSR180711 was visualized much more
clearly in the VT images than in the static images. At baseline, the
radioactivity in three of the four brain regions increased gradually
over 90 min, with the exception being the cerebellum, where the
radioactivity reached a plateau at 40 min. Under the SSR180711-
blocking condition, the accumulation of radioactivity occurred
slightly more quickly, reached a plateau at 40–60 min, and then
decreased slightly. Both the total and metabolite-corrected plasma
radioactivity decreased rapidly (data not shown).
The percentages of the unchanged form of [
11C]A-844606
rapidly decreased in baseline (n=3): 83.262.9%, 78.362.5%,
68.764.8%, 53.663.3%, 46.967.3%, 28.2613.9%, 21.065.4%,
22.264.9%, 14.964.7%, and 13.464.2%; and under the
SSR180711-blocking condition (n=1): 90.7%, 87.1%, 80.4%,
63.3%, 55.2%, 28.7%, 24.0%, 16.8%, 13.2%, and 10.2% at 0.3,
0.7, 1.1, 6.0, 10, 30, 45, 60, 75, and 90 min, respectively.
Figure 1. Radiosynthesis of [
11C]A-582941 and [
11C]A-844606.
doi:10.1371/journal.pone.0008961.g001
Table 1. Tissue distribution of radioactivity after intravenous
injection of [
11C]A-582941 into mice.
% Injected dose/g tissue (mean 6 S.D., n=4)
1 min 5 min 15 min 30 min 60 min
Blood 1.8460.43 0.8960.04 0.7660.06 0.6460.06 0.5760.05
Heart 4.3360.82 2.1660.13 1.7260.17 1.3960.10 1.0260.08
Lung 18.0964.18 12.5268.59 7.0260.10 6.0660.31 4.1360.15
Liver 3.5960.45 10.5260.69 12.3861.68 9.8760.80 7.2460.74
Pancreas 4.6560.76 7.4760.54 5.8060.80 4.6860.51 3.6960.42
Spleen 2.7060.31 5.5360.38 5.1360.72 3.6460.14 2.8960.90
Kidney 13.8761.58 8.7760.79 6.0260.97 4.8360.77 3.7460.20
S. intestine 3.1360.51 4.4960.60 4.6160.60 5.3361.20 4.5361.21
Muscle 2.0260.34 1.4060.16 1.0660.09 0.8260.07 0.6660.05
Brain 2.6160.33 3.9260.49 3.6360.28 2.6860.29 1.8560.10
doi:10.1371/journal.pone.0008961.t001
Table 2. Tissue distribution of radioactivity in mice after
intravenous injection of [
11C]A-844606.
% Injected dose/g tissue (mean 6 S.D., n=4)
1 min 5 min 15 min 30 min 60 min
Blood 1.0360.26 0.6360.08 0.5360.06 0.5460.06 0.4060.03
Heart 9.3461.26 4.0960.33 2.1160.12 1.6460.17 0.8560.12
Lung 45.8569.29 23.3961.09 13.9263.07 8.9862.04 3.6160.62
Liver 2.4960.77 4.4860.29 6.9060.34 7.5960.94 5.3960.46
Pancreas 3.7661.08 6.6761.25 7.7760.61 6.5260.72 2.6860.85
Spleen 1.7560.65 4.8460.71 7.3460.17 5.8261.29 2.4760.40
Kidney 12.3762.63 12.0160.91 8.6260.97 6.3860.98 2.9960.27
S. intestine 2.9260.88 4.7460.84 7.8660.97 9.6063.11 8.3560.42
Muscle 2.5360.61 1.9360.40 1.3560.20 1.0660.16 0.5560.06
Brain 4.1660.85 6.2660.97 7.3161.16 7.9660.62 4.2760.49
doi:10.1371/journal.pone.0008961.t002
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thalamus (138.6642.3; 95.0–179.4). frontal cortex (130.9640.4;
89.8–170.6). hippocampus (118.5633.6; 82.9–149.6). cerebel-
lum (95.2632.8; 62.1–127.7). The VT was significantly decreased
(,50%) by pretreatment with SSR180711 (Table 7).
Discussion
In the present study, we successfully obtained the carbon-11-
labeled selective a7 nAChR agonists A-582941 and A-844606,
which possessed an octahydropyrrolo[3,4-c]pyrrole core structure.
Methylation of N-, O-, or S-nucleophile with [
11C]methyl triflate is
the widely used tool for introducing a short-lived carbon-11
positron emitter into organic molecules. This strategy was
successfully employed in the radiosynthesis of [
11C]A-582941
and [
11C]A-844606 by reaction of the corresponding desmethyl-
precursors with [
11C]methyl triflate. The amount of the base was
optimized at two equivalent moles of the corresponding precursor.
We also investigated its in vivo target specificity in mice and
conscious monkeys.
Previous in vitro membrane-binding and pharmacological studies
showed the high affinity and selectivity of A-582941 and A-844606
for a7 nAChRs [27,28]. The target affinity of A-582941
(Ki=10.8 nM) and A-844606 (IC50=11 nM) was high in
comparison to the CHIBA-1001 (IC50=45.8 nM; Ki=35 nM),
of which a carbon-11-labeled analog has been used for imaging of
a7 nAChRs in a clinical study [21]. The Ki values for CHIBA-
1001 were calculated by the method of Cheng and Prusoff [29].
For calculation of the Ki value for CHIBA-1001, a value of
1.67 nM was used as the KD for a-bungarotoxin. These results
encouraged us to evaluate the possibility of using [
11C]A-582941
and A-844606 for the in vivo imaging of a7 nAChRs in the brain.
In the in vivo distribution study in mice, both tracers showed
high brain uptake. [
11C]A-844606 showed higher brain uptake
Table 3. Effects of co-injection of the subtype-selective
nAChRs agonists on the brain tissue uptake of radioactivity
15 min after injection of [
11C]A-582941 into mice.
% Injected dose/g tissue (mean 6 S.D., n=5)
Control A-85380 A-844606 SSR180711
Blood 0.8860.10 0.8560.06 0.9160.10 1.0660.09 **
Cerebellum 3.7160.19 3.7660.50 3.6260.10 3.3260.25
Medulla oblongata 4.2360.08 3.9960.49 4.0460.19 3.1560.14*
Hypothalamus 3.5160.60 3.9760.65 3.5060.87 3.4960.36
Hippocampus 4.0560.52 3.9260.54 4.2060.55 4.6360.51
Striatum 4.0360.45 4.3360.75 3.9460.89 4.1961.04
Midbrain 4.0960.52 4.5260.68 4.2960.11 3.9160.45
Cerebral cortex 4.5960.25 4.5360.61 4.7860.19 5.0260.46
Whole brain 4.2360.23 4.2660.57 4.2760.18 4.2160.39
Significant differences (p,0.05): *decrease and **increase compared to the
control (ANOVA with Bonferroni’s post-hoc tests).
The co-injected dose of each nAChRs agonist was 1 mg/kg.
doi:10.1371/journal.pone.0008961.t003
Table 4. Effects of carrier-loading on the brain tissue uptake
of radioactivity 15 min after injection of [
11C]A-582941 into
mice.
% Injected dose/g tissue (mean 6 S.D., n=5)
Control 0.01 mg/kg 0.1 mg/kg 1.0 mg/kg
Blood 0.7460.11 0.7460.06 0.8460.10 0.8860.11
Cerebellum 2.7360.21 2.6260.16 2.7660.48 2.3360.38
Medulla oblongata 3.6660.24 3.1860.35 3.3060.41 2.6360.29*
Hypothalamus 3.1060.38 2.8760.56 3.1560.31 2.7960.33
Hippocampus 3.2460.62 3.1860.38 3.6160.41 3.2860.31
Striatum 3.3660.38 3.3060.25 3.6160.27 3.4560.19
Midbrain 3.7060.29 3.0260.41* 3.2560.14 3.0560.27*
Cerebral cortex 4.0860.50 3.6460.40 3.9860.31 3.7560.40
Whole brain 3.6360.35 3.2560.30 3.5360.30 3.2260.32
*Significant decrease (p,0.05) compared to the control (ANOVA with
Bonferroni’s post-hoc tests).
doi:10.1371/journal.pone.0008961.t004
Table 5. Effects of co-injection of the subtype-selective
nAChRs agonists on the brain tissue uptake of radioactivity
30 min after injection of [
11C]A-844606 into mice.
% Injected dose/g tissue (mean 6 S.D., n=5)
Control A-85380 A-582941 SSR180711
Blood 0.5760.11 0.5460.12 0.6160.07 0.5260.06
Cerebellum 4.5460.63 6.2261.26 5.1760.97 5.1060.69
Medulla oblongata 5.2560.95 5.4661.15 5.5861.26 5.3560.33
Hypothalamus 4.2161.55 5.0060.96 4.7661.17 4.7460.70
Hippocampus 4.4660.90 5.5861.26 6.4861.31 6.2660.64
Striatum 5.0162.00 6.4761.38 6.8161.05 7.3261.84
Midbrain 5.4360.75 6.8461.71 5.8061.46 6.6960.79
Cerebral cortex 7.6360.98 7.5761.48 8.3861.22 8.4361.07
Whole brain 5.8360.56 6.6461.33 6.7161.09 6.8260.64
No significant differences (p,0.05) between the control and each drug-treated
group (ANOVA with Bonferroni’s post-hoc tests).
The co-injected dose of each nAChRs agonist was 1 mg/kg.
doi:10.1371/journal.pone.0008961.t005
Table 6. Effects of carrier-loading on the brain tissue uptake
of radioactivity 30 min after injection of [
11C]A-844606 into
mice.
% Injected dose/g tissue (mean 6 S.D., n=5)
Control 0.01 mg/kg 0.1 mg/kg 1.0 mg/kg
Blood 0.3860.06 0.2860.08 0.3360.02 0.2660.04*
Cerebellum 6.1960.58 4.7661.09* 4.8560.67 3.4960.46*
Medulla oblongata 6.4261.08 4.3860.54* 4.5960.48* 3.3760.36*
Hypothalamus 6.3962.01 3.9760.89* 4.0760.60* 3.7560.44*
Hippocampus 7.6662.58 4.5760.40* 4.6660.27* 4.1460.75*
Striatum 7.4362.04 4.5460.79* 5.3361.49 4.5760.99*
Midbrain 7.7161.29 4.9860.57* 5.6160.55* 3.9860.61*
Cerebral cortex 10.0860.57 7.0261.25* 6.8560.54* 5.2260.72*
Whole brain 8.0260.71 5.5460.83* 5.7360.34* 4.3460.61*
*Significant decrease (p,0.05) compared to the control (ANOVA with
Bonferroni’s post-hoc tests).
doi:10.1371/journal.pone.0008961.t006
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11C]A-582941. The hippocampal uptake of [
11C]A-582941
was not significantly higher than the cerebellar uptake at 15 min
after injection. In contrast, the hippocampal uptake of [
11C]A-
844606 was slightly higher than cerebellar uptake but not
significant at 30 min after injection. These findings indicate the
high nonspecific binding of [
11C]A-582941 and a few receptor-
specific binding of [
11C]A-844606 in the mouse brain, because a7
nAChRs density is high in the hippocampus and low in the
cerebellum in mice [4]. This high level of nonspecific binding of
[
11C]A-582941 was also confirmed in the competitive drug
treatment studies. Co-injection with the selective a7 nAChR
agonists SSR180711 and A-844606 did not decrease the regional
brain uptake of [
11C]A-582941. In the carrier-loading studies, a
significant decrease of radioactivity was observed only in the
medulla oblongata. These data imply that a limited fraction of the
[
11C]A-582941 taken up into the mouse brain was involved in
receptor-specific binding in vivo.
In the competitive drug treatment studies, co-injection with the
selective a7 nAChR agonists SSR180711 and A-582941 also could
not decrease the regional brain uptake of [
11C]A-844606. On the
other hand, the carrier-loading studies indicated a significant
decrease in uptake in both the hippocampus (target tissue) and
cerebellum (non-target tissue). These data suggest that saturable
binding sites of [
11C]A-844606 are present in the mouse brain but
may be different from a7 nAChRs in vivo.
However, it is well known that in vivo evaluations of specific
binding in mice have some limitations and sometimes lead to false-
negative results. First, the uptake studies employing dissected tissue
are usually performed at a single time-point that is reasonably
selected based on tissue time-activity curve (tTAC) obtained in the
tissue distributionstudy.The kinetic analysis of the PET study of the
monkeybrainindicatedthatthespecificbindingwas evaluatedfrom
overall data of the PET scan: 93 min scan in the present study.
Indeed, in our current study, the specific binding of the tracers in
mice was evaluated at the time of highest brain uptake under the
baseline condition. Second, in the in vivo evaluations of the specific
binding of tracers, pretreatment with blockers is usually more
effective than co-injection of the same blockers. In the present
studies using mice, the cold-displacement and blocking experiments
were performed using the co-injection method. Indeed, an
additional, unknown effect might have been produced by co-
injection of selective a7 nAChR agonists (A-582941 and
SSR180711) at a dose of 1 mg/kg, which resulted in enhanced
[
11C]A-844606 uptake in the brain tissues. When looking at the
tTACs in the monkey brain, an enhanced uptake of [
11C]A-844606
Figure 2. Baseline and SSR180711-blocking PET images of the
monkey brain with [
11C]A-582941. Upper: Static images acquired
from 70 to 90 min after injection of [
11C]A-582941, were expressed as a
standardized uptake value (SUV). Lower: Parametric images for the total
distribution volume of [
11C]A-582941 were generated using Logan
graphical analysis. SSR180711 (5 mg/kg) was intravenously injected into
the monkey 30 min before the injection of [
11C]A-582941.
doi:10.1371/journal.pone.0008961.g002
Figure 3. Time-activity curves of radioactivity in four brain regions (frontal cortex, thalamus, hippocampus, and cerebellum) and
metabolite corrected plasma after intravenous injection of [
11C]A-582941 in baseline and SSR180711-blocking PET scans. The
monkey was given intravenously saline and SSR180711 (5.0 mg/kg, i.v.) in the baseline (filled symbols) and SSR180711-blocking (open symbols) scans,
respectively, 30 min after injection of [
11C]A-582941. Radioactivity was expressed as a percentage of injected doses per ml of tissue (%ID/ml).
doi:10.1371/journal.pone.0008961.g003
Novel PET Ligands for a7 nAChR
PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e8961was also observed for approximately 60 min after the injection.
Similar phenomena have sometimes been observed during the
development of in vivo radioligands [30–32]. Moreover, we
previously reported that [
11C]doxepin was representative of a
radioligand engendering these phenomena [33]. Notwithstanding
the clinical usefulness of [
11C]doxepin PET for measurement of the
histamineH1 receptor occupancy rates of antihistamineagents [34],
the specific binding of [
11C]doxepin to histamine H1 receptors is
very low in rodents, and is not detected in guinea pigs. However,
kinetic analysisoftheresultsofa PETstudyof[
11C]doxepinshowed
30% specific binding in the monkey brain, and a larger specific
binding rate (36%) in the human brain [33]. As observed in the
[
11C]doxepin study using rodents, our negative results in mice are
hardly expected fromtheinvitrostudiescausethe target affinityofA-
582941 and A-844606 are higher than that of CHIBA-1001.
Theoretically, kinetic analysis of PET study results in the monkey
brain is far preferable to an uptake study using co-injection at a
single time-point in rodents. We therefore consider that more
suitable evaluations were performed by the monkey PET studies.
An in vivo PET study using conscious monkeys demonstrated a
high accumulation [
11C]A-582941 and [
11C]A-844606 in the
brain. In contrast to the mouse brain, the regional distribution of
both tracers in the monkey brain is consistent with the distribution
of a7 nAChRs. In rhesus monkeys, a7 nAChRs are distributed at
the highest level in the thalamus, at a moderate level in the cortex,
and at a low level in the cerebellum [35–38]. Figures 3 and 5
demonstrate a high uptake of both tracers in the thalamus and
cortical regions and a low uptake in the cerebellum. However, the
regional differences were small and the average VT ratio of the a7
nAChR-rich thalamus to the a7 nAChR-poor cerebellum was
below ,2.0. Distinct from the mice data, the uptake of both
tracers in the monkey brain regions was blocked by pretreatment
with the selective a7 nAChR agonist SSR180711. Because the 1,4-
diazabicyclo-[3.2.2]nonane skeleton of SSR180711 is different
from the 3,7-diazabicyclo[3.3.0]octane skeleton of A-582941 and
A-844606, this data might indicate the selectivity of [
11C]A-
582941 and [
11C]A-844606 for a7 nAChRs. However, these
positive characteristics, which indicate the specific binding of the
tracer to a7 nAChRs, were diminished by the fact that these
compounds also showed the same levels of blocking in the
cerebellum. On the other hand, the possibility that the uptake of
these tracers was due to the existence of a7 nAChRs in the
cerebellum has not been ruled out. In fact, a human postmortem
brain study has shown that [
125I]a-bungarotoxin binding in the
cerebellum is at the same level as that of the cortex [39,40]. In the
monkey brain, the a7 nAChR mRNA expression pattern
resembles that of the postmortem human brain [40,41].
Quantitative analysis lead out the significant VT reduction in the
brain regions of these tracers pretreated with SSR180711.
However, the inter-subject differences of VT in the baseline scan
of these tracers were massive, and this difference was at the same
level as the VT reduction in the blocking study. VT is the ratio at
equilibrium of the total tissue concentration to the metabolite-
corrected plasma concentration. Therefore, not only the changes
of tTAC but also the changes of the plasma time activity curve
(pTAC) will affect the VT. Indeed, the integral of pTAC of these
tracers was obviously increased with SSR180711 pretreatment
(data not shown), and might have caused the significant VT
reduction in the brain regions of these tracers.
Nevertheless, as mentioned above, the 30–50% VT reduction
rate was larger than that of [
11C]doxepin (30%) in the monkey
Table 7. Total distribution volume (VT)o f[
11C]A-582941 and [
11C]A-844606 in the baseline and SSR180711 pre-treatment
conditions and receptor blocking rate by SSR180711 (n=1).
[
11C]A-582941 [
11C]A-844606
VT (ml/g) VT (ml/g)
Baseline SSR180711 % decrease* Baseline SSR180711 % decrease*
Cerebellum 25.4 17.3 32.0 95.9 52.8 45.0
Frontal cortex 34.5 23.0 33.4 132.2 65.3 50.6
Thalamus 34.0 23.6 30.5 141.5 69.3 51.0
Hippocampus 31.6 20.4 35.5 123.1 57.5 53.3
*VT decrease was calculated as follow: [(VT of baseline) – (VT of SSR180711)]/(VT of baseline)6100.
doi:10.1371/journal.pone.0008961.t007
Figure 4. Baseline and SSR180711-blocking PET images of
monkey brain with [
11C]A-844606. Upper: Static images acquired
from 70 to 90 min after injection of [
11C]A-844606, were expressed as a
standarized uptake value (SUV). Lower: Parametric image for the total
distribution volume of [
11C]A-844606 were generated using Logan
graphical analysis. SSR180711 (5 mg/kg) was intravenously injected into
the monkey 30 min before the injection of [
11C]A-844606.
doi:10.1371/journal.pone.0008961.g004
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tracers in the experimental animals are still exists, these
compounds have chance to proceed to the preliminarily clinical
evaluation when the clinical safety of these tracers are confirmed.
A species difference in the peripheral metabolism of [
11C]A-
582941 was found between mice and monkeys. The finding that
[
11C]A-582941 was more stable peripherally in monkeys than in
mice is a good property for a PET ligand in monkeys: the
percentages of the intact form in the plasma of mice and monkeys
were 26.8% and 42.8%, respectively, at 30 min post-injection. In
contrast, a species difference between mice and monkeys was not
found in the peripheral metabolism of [
11C]A-844606. The
percentages of the intact form in the plasma of mice and monkeys
were 28.9% and 28.2%, respectively, at 30 min post-injection.
A-582941 exhibits favorable physical properties for a CNS-
active drug, with a low molecular weight (280 Da for the free base)
and moderate lipophilicity (clog P=2.3) [28]. The molecule
possesses two basic sites, the N-methylated tertiary amine and
aminopyridazine, with pKa values of 8.75 and 4.44, respectively.
At physiological pH, the molecule exists substantially in the
monoprotonated state, and the log D at pH 7.4 is estimated to be
1.0. A-844606 also possesses one basic site, the N-methylated
tertiary amine. Perhaps ion-pair interactions between the basic
nitrogen and the charged acidic head groups of phospholipids
membranes induce nonspecific binding. Although we cannot
identify the cause of the species difference between mice and
monkeys, some structural characteristics might be responsible for
the high nonspecific binding in the mouse brain.
In general, a radioligand for in vivo imaging of neuronal
receptors should possess the following properties: 1) a high signal-
to-noise ratio that is linked to high binding affinity and low
nonspecific binding, 2) good blood-brain barrier penetration and
rapid clearance from the blood, 3) appropriate kinetics, 4) high
receptor selectivity, 5) good radiation dosimetry/toxicology
properties, and 6) appropriate radiochemistry. From previous in
vitro and pharmacological studies of A-582941 and A-844606, we
confirmed the 4) high receptor selectivity. In this study, we also
confirmed that these compounds showed 2) good blood-brain
barrier penetration and rapid clearance from the blood, and 6)
appropriate radiochemistry. Also, the regional brain uptake of
these compounds reached equilibrium with an
11C imaging time
window. However, our results also showed that improvements and
further considerations of categories 1) and 5) criteria are still
needed. Although most studies of the distribution of a7 nAChRs in
the brain are qualitative, one study using [
125I]MLA showed a
maximum number of binding sites of 6863 fmol/mg proteins in
the rat cerebral cortex and another, using [
3H]MLA, demonstrat-
ed 5964 fmol/mg in the mouse hippocampus [4,41]. These a7
nAChR concentrations suggest that ligands with low nanomolar
affinities should be successful for imaging a7 nAChRs in vivo.
Indeed, with a Kd of 10 nM, comparable to A-582941 and A-
844606, and a Bmax of 70 fmol/mg (,7 nM), the Bmax/Kd value is
calculated at ,1. This also indicates that further structural
modification of octahydropyrrolo[3,4-c]pyrrole analogs toward
high binding affinity may provide suitable imaging agents for a7
nAChRs. Very recently, Bunnelle et al. [42] reported that the
replacement of the terminal phenyl of A-582941 by an indolyl
group resulted in a potent and selective a7 ligand (Ki=0.24 nM;
.400,000-fold selective vs. a4b2-subtype). However, as stated by
Ding et al. [43], we have to keep in mind that the high in vitro
affinity of a ligand does not guarantee its suitability as an in vivo
ligand. The poor ability to predict the behavior of chemical
compounds in vivo based on log P values and affinities emphasizes
the need for more knowledge in this area.
The specific activities of a7 nAChRs radioligands is an
important factor to be considered. First, a radioligand of low
mass is required so as not to saturate the binding sites. Second, use
of radiotracers with more highly specific activity is more likely to
ensure that the radiolabeled compound does not elicit any
pharmacological effects when administered. Therefore, an ideal
in vivo radiotracer for the a7 nAChRs should be an antagonist.
However, a radiolabeled antagonist for a7 nAChRs with
sufficiently high affinity for in vivo imaging has yet to be identified.
In conclusion, although an inter-species difference in the
distribution of [
11C]A-582941 and [
11C]A-844606 was observed
between rodents and non-human primates, our non-human
primate study of [
11C]A-582941 and [
11C]A-844606 will present
a helpful leads to finding the novel useful PET ligands for imaging
Figure 5. Time-activity curves of radioactivity in four brain regions (frontal cortex, thalamus, hippocampus, and cerebellum) and
metabolite corrected plasma after intravenous injection of [
11C]A-844606 in baseline and SSR180711-blocking PET scans. The
monkey was given intravenously saline and SSR180711 (5.0 mg/kg, i.v.) in the baseline (filled symbols) and SSR180711-blocking (open symbols) scans,
respectively, 30 min after injection of [
11C]A-844606. Radioactivity was expressed as a percentage of injected doses per ml of tissue (%ID/ml).
doi:10.1371/journal.pone.0008961.g005
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octahydropyrrolo[3,4-c]pyrrole may be a lead structure with high
affinity and with functional groups that can be labeled with PET
isotopes.
Materials and Methods
General
The reference compounds (A-582941 and A-844606) and their
desmethyl precursors (desmethyl-A-582941 and desmethyl-A-
84606) were synthesized according to the method described
previously [23,24,28]. SSR180711 was also synthesized by a
previously described method [21]. All other chemical reagents were
obtained from commercial sources. Male ddY mice were obtained
from Tokyo Laboratory Animals Co., Ltd (Tokyo, Japan). The
animal studies were approved by the institutional ethics committees
for animal experiments at the Tokyo Metropolitan Institute of
Gerontology and Chiba University. The PET study with monkeys
was approved by the institutional ethics committees for animal
experiments at the Hamamatsu Photonics K.K. and Chiba
University. The PET study with monkeys was performed at the
Central Research Laboratory of Hamamatsu Photonics K.K.,
Hamamatsu, Japan, in accordance with recommendations of the
U.S. National Institutes of Health and the guidelines of the Central
Research Laboratory, Hamamatsu Photonics K.K. Monkeys were
monitored closely and animal welfare is assessed on a daily basis,
and if necessary several times a day. This includes veterinary
examinations to make sure animals are not suffering. If animals
experience pain they receive pain medications. If pain can not be
relieved, or if veterinary examination reveals signs of suffering that
cannot be relieved by analgesics, antiemetics, or antibiotic therapy,
animals are euthanized.
2-[
11C]Methyl-5-[6-phenylpyridazine-3-yl]octahydropyrrolo
[3,4-c]pyrrole ([
11C]-A-582941). [
11C]A-582941 was synthesized
by [
11C]methylation of desmethyl-A-582941 with [
11C]methyl triflate
prepared using an automated synthesis system as previously described
(Figure 1) [44]. [
11C]Methyl triflate was trapped in acetone (0.25 ml)
containing 0.25 mg (1 mmol) of desmethyl-A-582941 and 10 ml
(2 mmol) of 0.2 M aqueous NaOH as a base. The reaction was
carried out at room temperature for 1 min. After 1.3 ml of CH3CN/
50 mM CH3COONH4 (20/80, v/v) had been added, the reaction
mixture was applied to HPLC using a reverse phase column (YMC-
Pack ODS-A: 10 mm inner diameter 6250 mm length; YMC Co.,
Ltd., Kyoto, Japan) together with a UV absorbance detector (260 nm)
and a semiconductor radiation detector. The mobile phase was a
mixture of CH3CN and 50 mM CH3COONH4 (20/80, v/v) at a
flow rate of 6 ml/min. The [
11C]A-582941 fraction (retention time:
15.7 min for [
11C]A-582941 and 7.7 min for desmethyl-A-582941)
was corrected and evaporated to dryness. The residue was dissolved in
physiological saline and filtered through a 0.22 mm membrane. The
labeled compound was analyzed by HPLC using a TSKgel Super-
ODS column (4.6 mm inner diameter6100 mm length; Tosoh Co.,
Ltd., Tokyo, Japan); the mobile phase was CH3CN/50 mM
CH3COONH4 (35/65, v/v), the flow rate was 1.0 ml/min, and the
retention time was 5.1 min for [
11C]A-582941.
2-(5-[
11C]Methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-
xanthene-9-one ([
11C]A-844606). [
11C]A-844606 was pre-
pared by a method similar to that for [
11C]A-582941 with a slight
modification in HPLC separation—namely, desmethyl-A-844606
(0.25 mg, 1 mmol) was used as the labeling precursor (Figure 1).
After 1.3 ml of CH3CN/50 mM CH3COONH4 (35/65, v/v) had
been added, the reaction mixture was applied to HPLC using the
same reversed phase column. The mobile phase was a mixture of
CH3CN and 50 mM CH3COONH4 (35/65, v/v) at a flow rate of
6 ml/min and the retention times were 11.8 min for [
11C]A-
844606 and 6.3 min for desmethyl-A-844606. Then the [
11C]A-
844606 fraction prepared for injection was analyzed by the same
HPLC with a different mobile phase consisting of CH3CN/H2O/
triethylamine (65/35/0.1, v/v) and a retention time of 7.0 min for
[
11C]A-844606.
Tissue Distribution of the Tracers in Mice
Each tracer was intravenously injected into mice, and then the
animals were killed by cervical dislocation at 1, 5, 15, 30 and
60 min after injection (n=4). The body weight of the mice was
34.761.2 g. The injected doses of tracers were 2 MBq/0.049–
0.051 nmol. Blood was collected by heart puncture and tissues
were harvested. The carbon-11 in the samples was counted with
an auto-gamma-counter (LKB Wallac Compu-gamma 1282CS,
Turku, Finland) and the tissues were weighed. The tissue uptake of
carbon-11 was expressed as the %ID/g.
In the other group of mice, a blocking experiment to determine
the a7 nAChRs-specific regional brain uptake of the tracers was
carried out. Each tracer (2 MBq/0.055–0.096 nmol) was co-
injected with each of the following blockers into mice, and 15
([
11C]A-582941) or 30 ([
11C]A-844606) min later the mice were
killed (n=5) and the tissue uptake of
11C was expressed as the
%ID/g. The co-injected blockers were unlabeled A-582941 and
A-844606, SSR180711 (a7n AChRs selective agonist, a7
nAChRs, IC50=30 and 18 nM for rat and human receptors of
brain homogenates, respectively; a4b2, IC50.50,000 nM for
human receptor) [45] or A-85380 (a4b2 nAChRs selective agonist,
a7 nAChRs, Ki=100 and 148 nM for rat and human receptors of
brain homogenates, respectively; a4b2, Ki=0.05 and 0.04 nM for
rat and human receptors of brain homogenates, respectively) [46].
Each blocker was dissolved in 1N HCl to 40 mg/ml and diluted
up to 0.4 mg/ml with saline. The co-injected dose was 1 mg/kg.
In the control mice the same amount of 0.01 N HCl in saline was
co-injected.
To investigate the carrier-loading effect of the tracer uptake in
the mouse brain, each tracer (2 MBq/0.053–0.179 nmol) was co-
injected with unlabeled A-582941 or A-844606. The co-injected
doses were 0.01, 0.1 and 1 mg/kg. In the control mice, the same
amount of 0.01 N HCl in saline was co-injected. Fifteen ([
11C]A-
582941) or 30 ([
11C]A-844606) min later the mice were killed
(n=5) and the tissue uptake of
11C was expressed as the %ID/g.
Metabolite Analysis
Each tracer (180 MBq/3.0–13.4 nmol) was intravenously
injected into mice, and 15 and 30 min later the animals were
killed by cervical dislocation (n=3). Blood was removed by heart
puncture using a heparinized syringe, and the brain was removed.
The blood was centrifuged at 7,0006g for 1 min at 4uC to obtain
plasma, which was denatured with 5 volume of CH3CN. The
mixture was centrifuged under the same conditions, and the
precipitate was re-suspended in 0.5 ml of CH3CN, followed by
centrifugation. This procedure was repeated three times. The
cerebral cortex (approximately 200 mg) was homogenized in
1.0 ml of 50% CH3CN. The homogenate was then treated as
described above. The combined supernatant was diluted with 2
volumes of water and then analyzed by HPLC with a radioactivity
detector (FLO-ONE 150TR; Packard Instrument, Meriden, CT).
A Radial-Pak C18 column equipped with an RCM 8610 module
(8 mm 6100 mm; Waters, Milford, MA) was used with a mixture
of CH3CN/H2O/triethyl amine (40/60/0.1 for [
11C]A-582941
and 70/30/0.1 for [
11C]A-844606, v/v/v) as the mobile phase at a
flow rate of 2 ml/min. The elution profile was monitored with a
radioactivity detector. The retention times of [
11C]A-582941 and
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11C]A-844606 were 6.4 and 8.8 min, respectively. The recovery
in the eluate of the injected radioactivity was essentially
quantitative.
PET Study in Conscious Monkeys
Four young-adult male rhesus monkeys (Macaca mulatta)
weighing from 4 to 6 kg were used for PET measurements. The
monkeys were trained for the protocol as described previously
[21]. The magnetic resonance images (MRI) of all monkeys were
obtained with a Toshiba MRT-50A/II (0.5T) under anesthesia
with pentobarbital. The stereotactic coordinates of PET and MRI
were adjusted based on the orbitomeatal (OM) line with monkeys
secured in a specially designed head holder [47]. At least 1 month
before the PET study, an acrylic plate, with which the monkey was
fixed to the monkey chair, was attached to the head under
pentobarbital anesthesia as described previously [48].
PET data were collected on a high-resolution PET scanner
(SHR-7700; Hamamatsu Photonics K.K., Hamamatsu, Japan).
The camera consists of 16 detector rings and acquires 20 slices at a
center-to-center interval of 3.6 mm with a transaxial resolution of
2.6 mm full width at half maximum [49]. After an overnight fast,
the monkey was fixed to the monkey chair with stereotactic
coordinates aligned parallel to the OM line. A cannula was
implanted in the posterior tibial vein, and [
11C]A-582941 or
[
11C]A-844606 (1152–1336 MBq/26.8–63.1 nmol) was injected
into the monkey through the venous cannula. PET images were
acquired over 91 min (10 sec66 frames, 30 sec 66 frames, 1 min
612 frames, and 3 min 625 frames). PET scans were recon-
structed using a filtered backprojection method in a 1006100
matrix, with a voxel size of 1.2 mm61.2 mm63.6 mm. Summed
image of late phase (from 70 to 91 min post-injection) was
calculated as a static SUV (activity/ml tissue)/(injected activity/g
body weight) image. Each MRI was coregistered to an early (from
0 to 20 min) summed image using normalized mutual information,
and ROIs were placed on the summed image with reference to the
coregistered MRI. Three monkeys underwent [
11C]A-582941
scan morning, and then two of the three monkeys underwent
[
11C]A-844606 afternoon (baseline). Within 6 months the last one
of the three monkeys underwent two [
11C]A-844606 scans in the
baseline (morning) and blocking (afternoon) conditions 30 min
after injection of SSR180711 (5.0 mg/kg, i.v.), and the fourth
monkey underwent two [
11C]A-582941 scans in the baseline and
blocking conditions in the same way. Due to the very short half-life
of
11C (20.4 min), a time lag of at least 3 hours between the two
PET scans in an individual monkey in the same day provided a
sufficient decay time of radioactivity (approximately 1/400 of the
injected dose). Therefore, the level of radioactivity associated with
the previous injection of labeled compound did not interfere with
the next scan, as previously reported [50,51].
For the semi-quantitative analysis of PET data, arterial samples
were obtained every 8 sec from injection to 64 sec, and then again
at 1.5, 2.5, 4, 6, 10, 20, 30, 45, 60, and 90 min after each tracer
injection. Blood samples were centrifuged to separate the plasma,
weighed, and subjected to radioactivity measurement. For
metabolite analysis, methanol was added to some plasma samples,
the resulting solutions were centrifuged, and the supernatants were
developed with TLC plates (AL SIL G/UV; Whatman, Kent,
UK) using a mobile phase of dichloromethane/diethyl ether/
ethanol/triethylamine (20/20/2/2, v/v/v/v). At each sampling
time point, the ratio of radioactivity in the unmetabolized fraction
to that in the total plasma (metabolite plus unmetabolite) was
determined using a phosphoimaging plate (BAS-1500 MAC; Fuji
Film Co., Tokyo, Japan). The pTACs corrected for metabolite
were obtained. The tTACs in each region of interest (ROI) in the
brain were calculated as the %ID/ml or as a standardized uptake
value (SUV), (activity/ml tissue)/(injected activity/g body weight).
Using the tTACs and the metabolite-corrected pTAC, the VT for
each tracer was evaluated by Logan graphical analysis [52].
Statistical Analysis
A one-way analysis of variance (ANOVA) with Bonferroni’s
post-hoc tests was used in comparing treated groups to controls.
Differences with a p value,0.05 were considered to be statistically
significant.
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